These cholesterol-regulating phenomenon might attribute to its effect on down-regulating the expression of lipid-related markers such as SREBP2 and HMGCR, which may exert a protective role in the NAFLD treatment. The gene discussed is SREBF2; the disease is metabolic dysfunction-associated steatotic liver disease.